Gabapentin
Product Images NDC 58517-060

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 58517-060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by New Horizon Rx Group, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (01e45240 Figure 01)

Chemical Structure (01e45240 Figure 01)
FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (01e45240 Figure 02)

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (01e45240 Figure 02)
FDA Label Image

Figure 2.  Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (01e45240 Figure 03)

Figure 2.  Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (01e45240 Figure 03)
This is a study report about the mean pain score during a week dose titration period followed by a fixed dose period. The data compares the placebo effect with two different doses of Gabapentin (1800 mg/day and 2400 mg/day) over a period of 7 weeks. The study concluded that both doses of Gabapentin significantly reduced the mean pain score compared to the placebo (p<001). No further information about the study or the source is available from the given text.*
FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (01e45240 Figure 04)

Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (01e45240 Figure 04)
FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study (01e45240 Figure 05)

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study (01e45240 Figure 05)
FDA Label Image

01e45240-figure-06 (01e45240 Figure 06)

01e45240-figure-06 (01e45240 Figure 06)
This appears to be a prescription medication label for Gabapentin capsules in the US. The medication is provided in the form of capsules, and the total cost is listed as €101. The label also includes various codes and identifiers, such as "NDC 58517-060-30" and "2900£ V1".*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.